Antidepressants are a type of medicine used to treat major depressive disorder, some anxiety disorders, some chronic pain conditions, obsessive-compulsive disorder (OCD) and to help manage some addictions. Paroxetine HCl is a selective serotonin reuptake inhibitor anti-depressant with poor bioavailability and aqueous solubility. The aim of the present study was to design paroxetine HCl solid lipid nano-particles and to evaluate them. The paroxetine HCl loaded solid lipid nanoparticles were prepared by using the different lipids like tristearin and GMS with tween 80 as a surfactants in combination with soy lecithin as a stabilizer by hot melt homogenization followed by ultra-sonication method. FTIR studies confirmed that there was no interaction between the drug and lipids used. The prepared paroxetine HCl SLNs are characterized for particle size, zeta potential, polydispersity index, entrapment efficiency, drug content and in-vitro drug release. The particle size of paroxetine HCl SLNs ranged from 44.53 to 166.9 nm. The PDI of all formulations were good within the range of 0.270 to 0.485. The zeta potential of drug loaded SLN with lipids (TS and GMS) showed zeta potential ranged from -10.1 to -25.9 mV. Entrapment efficiency of all formulations was within the range of 78.93 to 95.09 %. The cumulative percentage release of optimized formulation (F2) showed good release after 24 hr (90.41 %). The percentage release kinetic studies showed that the release was first order diffusion controlled and the n value (0.42) obtained from the Korsmeyer-Peppas model indicated the release mechanism was Quasi-Fickian type.
Loading....